ایمونوتراپی برای COVID-19
ترجمه نشده

ایمونوتراپی برای COVID-19

عنوان فارسی مقاله: امکان ایمونوتراپی برای COVID-19: یک بررسی سیستماتیک
عنوان انگلیسی مقاله: The possible of immunotherapy for COVID-19: A systematic review
مجله/کنفرانس: ایمونوفارکولوژی بین المللی – International Immunopharmacology
رشته های تحصیلی مرتبط: پزشکی، داروسازی
گرایش های تحصیلی مرتبط: ویروس شناسی پزشکی، بیماری های عفونی، ایمنی شناسی پزشکی یا ایمونولوژی، پزشکی مولکولی، داروسازی بالینی
کلمات کلیدی فارسی: کروناویروس جدید ۲۰۱۹، کووید ۱۹، ایمونوتراپی، آنتی بادی مونوکلونال، واکسن، اینترلوکین
کلمات کلیدی انگلیسی: nCoV 2019، COVID-19، Immunotherapy، Monoclonal antibody، Vaccine، Interleukin
نوع نگارش مقاله: مقاله مروری (Review Article)
نمایه: Scopus – Master Journals List – JCR
شناسه دیجیتال (DOI): https://doi.org/10.1016/j.intimp.2020.106455
دانشگاه: Cellular and Molecular Research Center, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran
ناشر: الزویر - Elsevier
نوع ارائه مقاله: ژورنال
نوع مقاله: ISI
سال انتشار مقاله: 2020
ایمپکت فاکتور: 3.379 در سال 2019
شاخص H_index: 98 در سال 2020
شاخص SJR: 0.953 در سال 2019
شناسه ISSN: 1567-5769
شاخص Quartile (چارک): Q2 در سال 2019
فرمت مقاله انگلیسی: PDF
تعداد صفحات مقاله انگلیسی: 4
وضعیت ترجمه: ترجمه نشده است
قیمت مقاله انگلیسی: رایگان
آیا این مقاله بیس است: خیر
آیا این مقاله مدل مفهومی دارد: ندارد
آیا این مقاله پرسشنامه دارد: ندارد
آیا این مقاله متغیر دارد: ندارد
کد محصول: E14869
رفرنس: دارای رفرنس در داخل متن و انتهای مقاله
فهرست انگلیسی مطالب

Abstract


۱٫ Background


۲٫ Methods


۳٫ Results


۴٫ Results


۵٫ Discussion


۶٫ Conclusion


Acknowledgments


Declaration of Competing of Interest


Authors’ contributions


Funding


Appendix A. Supplementary data


References

نمونه متن انگلیسی مقاله

Abstract


The novel coronavirus (2019-nCoV) is an emerging pathogen that was first described in late December 2019 and causes a severe respiratory infection in humans. Since the outbreak of COVID-19, international attention has raised to develop treatment and control options such as types of immunotherapies. The immunotherapy is an effective method for fighting against similar viral infections such as SARS-CoV, and MERS-CoV. These methods include several types of vaccines, monoclonal antibody candidates, and etc. This systematic review article was designed to evaluate the existing evidence and experience related to immunotherapy for 2019-nCoV. Web of Science (ISI), PubMed, and Scopus databases were used to search for suitable keywords such as 2019-nCoV, novel coronavirus, Immunotherapy, interleukin, vaccine and the related words for relevant publications up to 24.3.2020. The present systematic review was performed based on PRISMA protocol. Data extraction and quality valuation of articles were performed by two reviewers. 51 articles were the results of the search and based on the inclusions and exclusions criteria, 7 articles were included in the final review. As a conclusion of these studies demonstrated that although no serious research has been done on this subject at the time of writing this article, similar studies on the related viruses showed notable results. So immunotherapy for this virus can also be a suitable option.


Background


۲۰۱۹-nCoV a large enveloped virus with a positive sense, singlestranded RNA genome, is the third known coronavirus after SARS-CoV and MERS-CoV that was first identified in late December 2019 and causes severe respiratory illness and pneumonia-like infection in humans [1,2]. WHO has declared the pandemic outbreak of novel coronavirus (2019-nCoV) as a global health emergency. Immunotherapy is an efficient therapeutic option intervention against viral infections. Most immunotherapy attempts have been successful to fight against similar COVID-19 viruses such as SARS-CoV and MERS-CoV. The main methods in this regard include several vaccines and monoclonal antibody candidates. Furthermore, according to existing evidence in fighting against viral infections such as Ebola, influenza, SARS, and MERS plasma exchange can likely reduce the viral load and disease mortality [3,4]. In both SARS-CoV and SARS-CoV-2 viruses entry into the host cells is mediated by interaction of the receptor-binding domain (RBD) in S protein on virus outer-membrane and angiotensin-converting enzyme 2 (ACE2) on cell. So, these proteins can be the major potential targets for immunotherapy [1,5]. The increasing knowledge of MERS-CoV and SARS-CoV immunotherapies in recent years might increase the opportunities to design effective same therapeutics for novel coronavirus [3].

  • اشتراک گذاری در

دیدگاه خود را بنویسید:

تاکنون دیدگاهی برای این نوشته ارسال نشده است

ایمونوتراپی برای COVID-19
نوشته های مرتبط
مقالات جدید
لوگوی رسانه های برخط

logo-samandehi

پیوندها